A perda auditiva neurossensorial (PANS) é um tipo de perda auditiva na qual a causa raiz reside no ouvido interno, no órgão sensorial ou no nervo vestibulococlear. A PANS representa cerca de 90% dos casos relatados de perda auditiva. A PANS é geralmente permanente e pode ser leve, moderada, severa, profunda ou total. No entanto, se a perda ocorreu subitamente, é necessário tratamento imediato; a prednisona e outros tratamentos podem reverter a perda. Vários outros descritores podem ser usados dependendo do formato do audiograma, tais como: de alta frequência, de baixa frequência, em formato de U, com entalhe, com pico ou plana.
Introdução
O que você precisa saber de cara
Visão geral
A surdez neurossensorial não-sindrômica rara mitocondrial é uma condição genética que afeta a audição, causada por alterações no DNA mitocondrial. Ela se manifesta como perda auditiva do tipo neurossensorial, ou seja, decorrente de danos nas células sensoriais do ouvido interno ou nas vias nervosas que levam o som ao cérebro. Por ser não-sindrômica, a perda auditiva ocorre isoladamente, sem estar associada a outros sinais ou sintomas em outros órgãos. A doença é considerada rara e sua prevalência exata é desconhecida.[1][2]
Sinais e sintomas
Causas genéticas
A surdez neurossensorial não-sindrômica rara mitocondrial é causada por alterações (mutações) em genes localizados no DNA mitocondrial ou em genes nucleares que afetam a função mitocondrial. Os genes associados incluem: MT-TH, TFB1M, POU3F4, TRMU, MT-CO1, MT-TS1, MT-ND4 e MT-RNR1. A herança é do tipo mitocondrial, ou seja, é transmitida exclusivamente pela linhagem materna.[1][3][4]
Diagnóstico
Tratamento e manejo
Não há medicamentos específicos aprovados para o tratamento da surdez neurossensorial não-sindrômica rara mitocondrial. O manejo é focado no suporte auditivo, como o uso de aparelhos auditivos ou implantes cocleares, e no acompanhamento com fonoaudiólogo e otorrinolaringologista. No Brasil, a condição não possui cobertura específica pelo Sistema Único de Saúde (SUS).[1][3]
Prognóstico e qualidade de vida
Conteúdo informativo gerado e mantido automaticamente a partir de fontes oficiais (Orphanet, HPO, OMIM, SUS). Não substitui avaliação médica.
A **surdez neurossensorial não-sindrômica rara mitocondrial** é uma alteração genética rara que atinge a capacidade auditiva sem provocar outros problemas no organismo. Ela costuma ser notada ainda nos primeiros anos de vida da criança e pode piorar de forma gradual com o passar do tempo. A causa está ligada a mutações no DNA mitocondrial ou em genes nucleares responsáveis pela respiração celular. No Brasil, a doença não conta com um protocolo clínico oficial (PCDT) nem com medicamentos próprios distribuídos pelo SUS.
A perda auditiva neurossensorial (PANS) é um tipo de perda auditiva na qual a causa raiz reside no ouvido interno, no órgão sensorial ou no nervo vestibulococlear. A PANS representa cerca de 90% dos casos relatados de perda auditiva. A PANS é geralmente permanente e pode ser leve, moderada, severa, profunda ou total. No entanto, se a perda ocorreu subitamente, é necessário tratamento imediato; a prednisona e outros tratamentos podem reverter a perda. Vários outros descritores podem ser usados dependendo do formato do audiograma, tais como: de alta frequência, de baixa frequência, em formato de U, com entalhe, com pico ou plana.
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 2 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
8 genes identificados com associação a esta condição. Padrão de herança: Mitochondrial inheritance.
Deafness, X-linked, 2
A form of deafness characterized by both conductive hearing loss resulting from stapes (perilymphatic gusher) fixation, and progressive sensorineural deafness.
Deafness, aminoglycoside-induced
A form of sensorineural deafness characterized by moderate-to-profound hearing loss and mitochondrial inheritance. It is induced by exposure to aminoglycosides.
Leber hereditary optic neuropathy
A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.
Leber hereditary optic neuropathy
A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.
Variantes genéticas (ClinVar)
65 variantes patogênicas registradas no ClinVar.
Vias biológicas (Reactome)
27 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Surdez neurossensorial não-sindrômica rara mitocondrial
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Pesquisa e ensaios clínicos
Nenhum ensaio clínico registrado para esta condição.
Publicações mais relevantes
Early-Onset Hearing Loss in Leber's Hereditary Optic Neuropathy: A Case Report.
Leber hereditary optic neuropathy (LHON) is one of the most common mitochondrial disorders that is characterized in young adults and teenagers as bilateral, painless, subacute visual failure. Extraocular manifestations include neurological and cardiac features. Sensorineural hearing loss (SNHL) has not been reported as a clinical feature of this disorder. We report a patient diagnosed with LHON having the common m.11778G>A; p. Arg340 pathogenic variant who was also diagnosed with bilateral mild-to-moderate high-frequency SNHL as a neonate through our provincial newborn screening program. Genetic workup, including a next-generation sequencing "Comprehensive Hereditary Hearing Loss Panel" for common and non-syndromic hearing loss and sequencing of the mitochondrial genome, was negative for a second pathogenic variant. The infectious workup was negative. Non-enhanced magnetic resonance imaging of the brain and internal auditory canal was normal. To our knowledge, SNHL has not been reported before as a clinical feature of patients diagnosed with LHON, and hence this rare and unusual presentation merits reporting.
A case with short stature and proteinuria: atypical presentation of a family with m.3243A>G mutation.
The mitochondrial DNA (mtDNA) m.3243A>G mutation is one of the most common pathogenic mtDNA variants. The phenotypes associated with this mutation range from asymptomatic induviduals to well-defined clinical syndromes, or non-syndromic mitochondrial disorders. Variable clinical features in pediatric cases may cause difficulty in diagnosis. Kidney involvement in this mutation is uncommon and reported on a case-by-case basis. Here, we report on a patient with m.3243A>G mutation, who presented with short stature and proteinuria, and his family, who share the same genotype but exhibit different heteroplasmy levels in different tissues and variable phenotypes. A 15-year-old male patient was admitted to the pediatric endocrinology department with short stature. His examinations revealed nephrotic range proteinuria, hearing loss, impaired glucose tolerance, and Wolf-Parkinson-White syndrome. From family history, it was learned that diabetes mellitus (DM) and progressive sensorineural hearing loss were common in this family. The patient's mother, who had chronic kidney disease, DM, and hearing loss, had died suddenly for an unknown reason. Considering the family history, a genetic analysis was performed for mitochondrial disease. Mitochondrial DNA analysis revealed a m.3243A>G mutation with 47% heteroplasmy in blood, 62% heteroplasmy in buccal cells, and 96% heteroplasmy in urothelial cells in our patient. Short stature without any other complaint and renal involvement are rare findings in m.3243A>G mutation. In patients presenting with proteinuria, in the presence of conditions affecting many systems such as endocrine system pathologies, hearing loss, and cardiac pathologies, and in the presence of individuals with a similar family history of multiple organ involvement, mitochondrial diseases should be considered, and examined from this perspective. Our case illustrates the value of a detailed medical and family history.
The Mitochondrial tRNASer(UCN) Gene: A Novel m.7484A>G Mutation Associated with Mitochondrial Encephalomyopathy and Literature Review.
Mitochondrial tRNASer(UCN) is considered a hot-spot for non-syndromic and aminoglycoside-induced hearing loss. However, many patients have been described with more extensive neurological diseases, mainly including epilepsy, myoclonus, ataxia, and myopathy. We describe a novel homoplasmic m.7484A>G mutation in the tRNASer(UCN) gene affecting the third base of the anticodon triplet in a girl with profound intellectual disability, spastic tetraplegia, sensorineural hearing loss, a clinical history of epilepsia partialis continua and vomiting, typical of MELAS syndrome, leading to a myoclonic epilepticus status, and myopathy with severe COX deficiency at muscle biopsy. The mutation was also found in the homoplasmic condition in the mother who presented with mild cognitive deficit, cerebellar ataxia, myoclonic epilepsy, sensorineural hearing loss and myopathy with COX deficient ragged-red fibers consistent with MERRF syndrome. This is the first anticodon mutation in the tRNASer(UCN) and the second homoplasmic mutation in the anticodon triplet reported to date.
Expanding the clinical phenotype of IARS2-related mitochondrial disease.
IARS2 encodes a mitochondrial isoleucyl-tRNA synthetase, a highly conserved nuclear-encoded enzyme required for the charging of tRNAs with their cognate amino acid for translation. Recently, pathogenic IARS2 variants have been identified in a number of patients presenting broad clinical phenotypes with autosomal recessive inheritance. These phenotypes range from Leigh and West syndrome to a new syndrome abbreviated CAGSSS that is characterised by cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia, as well as cataract with no additional anomalies. Genomic DNA from Iranian probands from two families with consanguineous parental background and overlapping CAGSSS features were subjected to exome sequencing and bioinformatics analysis. Exome sequencing and data analysis revealed a novel homozygous missense variant (c.2625C > T, p.Pro909Ser, NM_018060.3) within a 14.3 Mb run of homozygosity in proband 1 and a novel homozygous missense variant (c.2282A > G, p.His761Arg) residing in an ~ 8 Mb region of homozygosity in a proband of the second family. Patient-derived fibroblasts from proband 1 showed normal respiratory chain enzyme activity, as well as unchanged oxidative phosphorylation protein subunits and IARS2 levels. Homology modelling of the known and novel amino acid residue substitutions in IARS2 provided insight into the possible consequence of these variants on function and structure of the protein. This study further expands the phenotypic spectrum of IARS2 pathogenic variants to include two patients (patients 2 and 3) with cataract and skeletal dysplasia and no other features of CAGSSS to the possible presentation of the defects in IARS2. Additionally, this study suggests that adult patients with CAGSSS may manifest central adrenal insufficiency and type II esophageal achalasia and proposes that a variable sensorineural hearing loss onset, proportionate short stature, polyneuropathy, and mild dysmorphic features are possible, as seen in patient 1. Our findings support that even though biallelic IARS2 pathogenic variants can result in a distinctive, clinically recognisable phenotype in humans, it can also show a wide range of clinical presentation from severe pediatric neurological disorders of Leigh and West syndrome to both non-syndromic cataract and cataract accompanied by skeletal dysplasia.
Is PNPT1-related hearing loss ever non-syndromic? Whole exome sequencing of adult siblings expands the natural history of PNPT1-related disorders.
PNPT1 is a mitochondrial RNA transport protein that has been linked to two discrete phenotypes, namely isolated sensorineural hearing loss (OMIM 614934) and combined oxidative phosphorylation deficiency (OMIM 614932). The latter has been described in multiple families presenting with complex neurologic manifestations in childhood. We describe adult siblings with biallelic PNPT1 variants identified through WES who presented with isolated severe congenital sensorineural hearing loss (SNHL). In their 40s, they each developed and then followed a nearly identical neurodegenerative course with ataxia, dystonia, and cognitive decline. Now in their 50s and 60s, all have developed the additional features of optic nerve atrophy, spasticity, and incontinence. The natural history of the condition in this family may suggest that the individuals previously reported as having isolated SNHL may be at risk of developing multisystem disease in late adulthood, and that PNPT1-related disorders may constitute a spectrum rather than distinct phenotypes.
Publicações recentes
Expanding the clinical phenotype of IARS2-related mitochondrial disease.
Is PNPT1-related hearing loss ever non-syndromic? Whole exome sequencing of adult siblings expands the natural history of PNPT1-related disorders.
Prevalence of TECTA mutation in patients with mid-frequency sensorineural hearing loss.
High prevalence of CDH23 mutations in patients with congenital high-frequency sporadic or recessively inherited hearing loss.
Genetic etiology study of the non-syndromic deafness in Chinese Hans by targeted next-generation sequencing.
📚 EuropePMCmostrando 7
Early-Onset Hearing Loss in Leber's Hereditary Optic Neuropathy: A Case Report.
Ear, nose, & throat journalA case with short stature and proteinuria: atypical presentation of a family with m.3243A>G mutation.
The Turkish journal of pediatricsThe Mitochondrial tRNASer(UCN) Gene: A Novel m.7484A>G Mutation Associated with Mitochondrial Encephalomyopathy and Literature Review.
Life (Basel, Switzerland)Expanding the clinical phenotype of IARS2-related mitochondrial disease.
BMC medical geneticsIs PNPT1-related hearing loss ever non-syndromic? Whole exome sequencing of adult siblings expands the natural history of PNPT1-related disorders.
American journal of medical genetics. Part APrevalence of TECTA mutation in patients with mid-frequency sensorineural hearing loss.
Orphanet journal of rare diseasesHigh prevalence of CDH23 mutations in patients with congenital high-frequency sporadic or recessively inherited hearing loss.
Orphanet journal of rare diseasesAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Surdez neurossensorial não-sindrômica rara mitocondrial.
É de uma associação que acompanha esta doença? Fale com a gente →
Doença com base genética
Um médico geneticista pode ajudar no diagnóstico de Surdez neurossensorial não-sindrômica rara mitocondrial e no aconselhamento genético da família.
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
A condição é provocada por mutações genéticas com herança mitocondrial, afetando genes como MT-RNR1, MT-CO1, TFB1M e TRMU. Essas alterações comprometem o suporte energético das células auditivas sem gerar malformações em outros órgãos.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
5 fontes citadas no texto · 8 publicações do grafo RarasNet (PubMed) · 5 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (2026). Surdez neurossensorial não-sindrômica rara mitocondrial. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/surdez-neurossensorial-nao-sindromica-rara-mitocondrial
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
Surdez neurossensorial não-sindrômica rara mitocondrial
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Identificador unificado
- fonte: MONDO
- Genética mendeliana
- fonte: OMIM
- Codificação WHO/SUS
- fonte: WHO ICD-10 / DATASUS
- CID-11 (futuro)
- fonte: WHO ICD-11
- NIH/GARD
- fonte: GARD (NIH)
- Dado público estruturado
- fonte: Wikidata